Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Recruiting 181Active not recruiting 143Completed 48Not yet recruiting 36Terminated 16Suspended 4Withdrawn 3Enrolling by invitation 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Plasma cell 4Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 10Breast Neoplasms 9Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Lung Neoplasms 6Glioblastoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hematologic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Ovarian Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neoplasm, Residual 2NSCLC 2

Interventions

mirdametinib 1daratumumab 1Specimen Handling 1Sirolimus 1Lenalidomide 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Suspended × Multiple Myeloma × 90 days × Clear all
NCT06876142 2026-05-27

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
54 enrolled
Plasma cell

Multiple Myeloma

NCT04955808 2026-05-13

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

National Cancer Institute (NCI)

Suspended
2,400 enrolled
BreastGastrointestinalGenitourinaryPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Multiple Myeloma, Prostatic Neoplasms

NCT06663046 2026-05-07

Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

Wondercel Biotech (ShenZhen)

Phase EARLY_PHASE1 Suspended
30 enrolled
Plasma cell

Multiple Myeloma

NCT06348147 2026-05-04

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

UNC Lineberger Comprehensive Cancer Center

Phase 2 Suspended
39 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡